The topic of coexisting aortic stenosis (AS) and cardiac amyloidosis (CA) has become a classic of contemporary cardiology due to the spread of transcatheter aortic valve replacement (TAVR) as a treatment for AS and the wide availability of bone scintigraphy as a non-invasive diagnostic standard for transthyretin-related amyloidosis (ATTR).

Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?

Rapezzi C.
;
Campo G.
2021

Abstract

The topic of coexisting aortic stenosis (AS) and cardiac amyloidosis (CA) has become a classic of contemporary cardiology due to the spread of transcatheter aortic valve replacement (TAVR) as a treatment for AS and the wide availability of bone scintigraphy as a non-invasive diagnostic standard for transthyretin-related amyloidosis (ATTR).
Rapezzi, C.; Giannini, F.; Campo, G.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2472159
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact